Biofortis   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Columbia MD United States (2002)

Organization Overview

First Clinical Trial
2008
NCT00706888
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

BioFortis | Biofortis; 211 East Lake Street; Addison, IL 60101 | Biofortis Clinical Research, Inc. | Biofortis Clinical Research, Inc. Addison, Illinois, United States, 60101 | Biofortis, Inc. | Biofortis, Inc Addison IL 60101 | Biofortis Innovation Services | Biofortis Innovation Services Addison, IL, United States, 60101 | Biofortis Innovation Services, a division of Merieux Nutrisciences, Inc. | Biofortis Mérieux Nutriscience | Biofortis, Merieux NutriSciences

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 3)

Glucose Intolerance (Phase 3)

Hypercholesterolemia (Phase 2)

Hypertriglyceridemia (Phase 3)

Insulin Resistance (Phase 3)

Obesity (Phase 3)

Pancreatitis (Phase 1)

Prediabetic State (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 43
  • # of Trial APIs: 49